FDA Anti-Infective Drugs Advisory Committee To Review Two Antibiotics
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson’s ceftobiprole and Theravance’s telavancin will be discussed Feb. 27-28.
You may also be interested in...
FDA Stalls J&J’s Doribax For Hospital-Acquired Pneumonia
Agency needs three more months, company says.
FDA Stalls J&J’s Doribax For Hospital-Acquired Pneumonia
Agency needs three more months, company says.
FDA Cancels Telavancin Advisory Panel Review 3 Days Before Meeting
Data submitted by Theravance/Astellas in response to an October FDA “approvable” letter for the antibiotic could be behind the agency’s decision.